Efficacy of combined antiviral therapy with pegylated interferon α-2a and ribavirin for chronic hepatitis C infection in intravenous drug users

Srpski Arhiv za Celokupno Lekarstvo

Volumn 138, Issue 1-2, 2010, Pages 43-49

  Ružić, Maja ^a   Fabri, Milotka ^a   Klašnja, Biljana ^a   Pobor, Marta ^a   Švarc, Daniela ^a   Jovelić, Aleksandra ^b   Fabri, Izabella ^c  

^a Clinical Centre of Vojvodina   (Serbia)

^b Institute of Cardiovascular Diseases Vojvodina   (Serbia)

^c UNIVERSITY OF NOVI SAD   (Serbia)

Author keywords

Chronic hepatitis C; Intravenous drug users; Pegylated interferon alfa; Ribavirin

Indexed keywords

ALPHA2A INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ARTICLE; DRUG COMBINATION; FEMALE; HEPATITIS C; HUMAN; MALE; MIDDLE AGED; SUBSTANCE ABUSE;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 77955082151     PISSN: 03708179     EISSN: None     Source Type: Journal    
DOI: 10.2298/SARH1002043R     Document Type: Article

References (31)

1. Hadziyannis SJ, Sette H, Morgan TR, Diago M, Marcellin P, Ramadori G, et al. Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004; 140:346-55.
2. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358:958-65.
3. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonsales FL, et al. Peginterferon alfa 2a plus ribavirin for chronic hepatitis C virusinfection. N Engl Med. 2002; 347:975-82.
4. Sulkowski MS, Thomas DL. Epidemiology and natural history of hepatitis C virus infection in injection drug users: implications for treatment. Clin Infect Dis. 2005; 40(Suppl 5):S263-9.
5. Doab A, Treloar C, Dore GJ. Knowledge and attitude about treatment for hepatitis C virus infection and barriers to treatment among injection drug users in Australia. Clin Infect Dis. 2005; 40(Suppl 5):S313-20.
6. Sex differences in injecting practices and hepatiis C: a systemic review of the literature. Canada Communicable Disease Report [serial on the internet]. July, 2004. [cited 2006, November, 14]. 30(14):[about 8 p]. Avaliable from: http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/04vol30/dr3014e.html.
7. Butterfield MI, Bosworth HB, Meador KG, Stechuchak KM, Essock SM, Osher FC. Gender differences in hepatitis C infection and risk among persons with severe mental illness. Psychiatr Serv. 2003; 54:848-53.
8. Fabri M, Klašnja B, Ružić M, Pobor M, Preveden T. Epidemiološke karakteristike hepatitis C virusne infekcije anti HCV pozitivnih osoba lečenih u Klinici za infektivne bolesti u Novom Sadu. Acta Infectologica Iugoslavica. 2004; 8:19-24.
9. Maher L, Jalaludin B, Chant KG, Jayasuria R, Sladden T, Kaldor JM, et al. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction. 2006; 101(10):1499-508.
10. Edlin BR, Kresina TF, Raymond DB, Carden MR, Gourevitch MN, Rich JD. Overcoming barriers to prevention, care, and treatment of hepatitis C in illitic drug users. Clin Infect Dis. 2005; 40(Suppl 5):S276-85.
11. Oshita M, Hayashi N, Kasahara A, Hagiwara H, Mita E, Naito M, et al. Increased serum hepatitis C virus RNA levels among alcoholic patients with chronic hepatitis C. Hepatology. 1994; 20(5):1115-20.
12. Schiff ER. The alcoholic patient with hepatitis C virus infection. Am J Med. 1999; 107:95S-99S.
13. Dokić Lj, Švirtlih N, Boričić I, Božić M, Popović N, Bojović K. Prirodni tok infekcije virusom hepatitisa C. Acta Infectologica Iugoslavica. 2004; 8:35-40.
14. Cromie SL, Jenkins PJ, Bowden DS, Dudley FJ. Chronic hepatitis C: effect of alcohol on hepatic activity and viral titre. J Hepatol. 1996; 25:821-6.
15. Hezode C, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, Zafrani ES. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology. 2005; 42:63-71.
16. Trepo C. Genotype and viral load as prognostic indicators in the treatment of hepatitis C. J Viral Hepat. 2000; 7:250-7.
17. Inglesby TV, Rai R, Astembroski J, Gruskin L, Nelson KE, Vlahov D, etal. A prospective, communitiy-based evaluation of liver enzymes inindividuals with hepatitis C after drug use. Hepatology. 1999; 29:590-6.
18. Yeh MM, Buskell ZJ, Seeff LB, Strader D, Wright EC, Goodman ZD. More severe parenchymal injury in chronic hepatitis C acquired by recent injecting drug use. J Clin Gastroenterol. 2005; 39:722-7.
19. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347:975-82.
20. McCormick PA, Keavney M, O' Toole S, Moloney J. Methadone and HCV treatment. Ir Med J. 2008; 101(10):316-7.
21. Stoove MA, Gifford SM, Dore GJ. The impact of injecting drug users on hepatitis C-related referral and treatment. Drug Alchol Depen. 2005; 77:81-6.
22. Sylvestre DL. Treating hepatitis C virus infection in active substance users. Clin Infect Dis. 2005; 41(Suppl 1):S79-82.
23. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology. 2001; 34:188-93.
24. Dalgard O, BjøK, Hellum K, Myrvang B, Skaug K, Gutigard B, et al; Construct Group. Treatment of chronic hepatitis C in injecting drugusers: 5 years' follow-up. Eur Addict Res. 2002; 8:45-9.
25. Plosker GL, Keating GM. Peginterefron alfa 2a (40KD) plus ribavirin:A review of its use in hepatitis C virus and HIV co-infection. Drugs. 2004; 64:2823-43.
26. Litwin AH, Soloway I, Gourevith MN. Intergrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities. Clin Infect Dis. 2005; 40(Suppl 5):S339-45.
27. Kresina TF, Khalsa J, Cesari H, Francis H. Hepatitis C virus and substance abuse: Medical management and developing models ofintegrated care - an introduction. Clin Infect Dis. 2005; 40(Suppl 5):S259-62.
28. Mehta SH, Cox A, Hoover DR, Wang XH, Mao Q, Ray S, et al. Protection against persistence of hepatitis C. Lancet. 2002; 359:1478-83.
29. Nešić Z. Klinička, hematološka, biohemijska, virusološka I histopatološka evaluacija efikasnosti i bezbednosti monoterapije (interferon alfa) i kombinovane terapije (interferon alfa plus ribavirin) u bolesnika sa hroničnim hepatitisom C [magistarska teza]. Beograd: Medicinski fakultet Univerziteta u Beogradu; 2002.
30. Musselman DH, Lawson JF, Gumnick AK, Manutunga S, Penna BA, Goodkin K, et al. Paroxetine for the prevention of depression induced by high-dose interferon. N Engl J Med. 2001; 344:961-6.
31. Marks DM, Park MH, Ham BJ, Han C, Patkar AA, Masand PS, et al. Paroxetine: safety and tolerability issues. Expert Opin Drug Saf.2008; 7(6):783-94.